Effect of Longbishu Capsule (癃闭舒胶囊) plus Doxazosin on Benign Prostatic Hyperplasia:A Randomized Controlled Trial  

作　　者：宋春生 郭军 常德贵 陈磊 张瑞 赵家有 王福 张强 

机构地区：[1]Graduate School of China Academy of Chinese Medical Sciences [2]Department of Andrology,Xiyuan Hospital,China Academy of Chinese Medical Sciences [3]Department of Urology and Andrology,Affiliated Hospital of Chengdu University of Traditional Chinese Medicine [4]Department of Urology,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine [5]Department of Andrology,the Second Affiliated Hospital to Heilongjiang University of Traditional Chinese Medicine

出　　处：《Chinese Journal of Integrative Medicine》2014年第11期818-822,共5页中国结合医学杂志（英文版）

基　　金：Supported by the Project of Science Research for the 11th FiveYear Plan(No.2007BAI20B044)

摘　　要：Objective：To investigate the effect of Longbishu Capsule（癃闭舒胶囊,LBS）,doxazosin,and combination therapy on benign prostatic hyperplasia（BPH）.Methods：A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing（108 cases）,Heilongjiang（90 cases）,Sichuan（90 cases）,Shanghai（72 cases）,China.They were randomly assigned with central randomization method to group A（LBS placebo plus doxazosin）,group B（LBS plus doxazosin）or group C（LBS plus doxazosin placebo）,120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results：At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline（P〈0.01）.Although postvoid residual urine volume was not significantly different from the baseline in group A（P〉0.05）,it significantly decreased in group B and C（P〈0.05）.The incidence of adverse events were similar among the three groups.Conclusions：The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.Objective：To investigate the effect of Longbishu Capsule（癃闭舒胶囊,LBS）,doxazosin,and combination therapy on benign prostatic hyperplasia（BPH）.Methods：A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing（108 cases）,Heilongjiang（90 cases）,Sichuan（90 cases）,Shanghai（72 cases）,China.They were randomly assigned with central randomization method to group A（LBS placebo plus doxazosin）,group B（LBS plus doxazosin）or group C（LBS plus doxazosin placebo）,120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results：At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline（P〈0.01）.Although postvoid residual urine volume was not significantly different from the baseline in group A（P〉0.05）,it significantly decreased in group B and C（P〈0.05）.The incidence of adverse events were similar among the three groups.Conclusions：The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.

关 键 词：benign prostatic hyperplasia combination therapy Longbishu Capsule doxazosin clinical progression Chinese medicine 

分 类 号：R697.3[医药卫生—泌尿科学]